It looks decisions were driven by assumptions than ground realities
With $32 billion worth of drugs going off patent in the next two years…
Thermal power sector is the most stressed sector, because of low availability of coal which attracts few buyers.
Indian and foreign generic drug makers seem to focus increasingly on the relatively fast-growing injectables segment to ramp up their…
In FY11 and FY12, by contrast, around 15% of those migrating were high-paying commercial and industrial users.
Lupin CEO Vinita Gupta acknowledged there will be pricing pressure because of mergers in supply chain space.
Maharashtra govt may want to make life easier for Mumbaikars by lowering power tariffs…
Western regulators have increased scrutiny of Indian drug manufacturing manufacturing plants to check if they adhere to good manufacturing practices.
GSK has seen sales flag after reducing margins for wholesalers and retailers.
Inadequate resources, coupled with rising demand, has proved to be a stumbling block for Indian pharmaceutical companies
India has 526 USFDA-approved units while China is home to over 960 such sites.
Fortis Healthcare, however, appears well-ensconced at the top slot for now.
The trend of relative higher growth in the chronic drugs segment has continued in the current calender year, going by…
Focusing on pharmaceutical innovation funded by revenue from generics, Glenn Saldanha
Despite seemingly strict criteria, pharmaceutical patents are not that hard to come by in India
Mercury-based fever thermometers and blood pressure devices could be a thing of the past.
